# DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

> **NCT02817451** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 53 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Polio
- Human Immunodeficiency Virus Infection

## Interventions

- **BIOLOGICAL:** Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
- **BIOLOGICAL:** Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine

## Key facts

- **NCT ID:** NCT02817451
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-14
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-02-22
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02817451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02817451, "DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02817451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*